MaxLinear (MXL) authorizes $75M stock repurchase through 2028

MaxLinear, Inc. reported that its board of directors has approved a share repurchase program authorizing the buyback of up to $75 million of its common stock through November 20, 2028.

Rhea-AI Filing Summary

MaxLinear, Inc. reported that its board of directors has approved a share repurchase program authorizing the buyback of up to $75 million of its common stock through November 20, 2028. Repurchases may be made in the open market, through block trades, or via privately negotiated transactions, including under Rule 10b5-1 trading plans, in compliance with Rule 10b-18. The program is discretionary, does not require the company to repurchase any shares, and can be modified, suspended, or terminated at any time based on factors such as liquidity, share price, market conditions, and legal requirements.

Insights

Equity capital allocation analyst

MaxLinear authorizes up to $75M in discretionary share repurchases through 2028.

MaxLinear has authorized a share repurchase program of up to $75,000,000 of its common stock, with a stated end date of November 20, 2028. Repurchases may occur via open market purchases, block transactions, or privately negotiated deals, and can also be executed under Rule 10b5-1 trading plans in line with Rule 10b-18.

The authorization is explicitly discretionary: the company is not obligated to repurchase any shares and may modify, suspend, or terminate the program at any time without prior notice. Actual activity will depend on factors such as liquidity, share price, overall market conditions, and legal constraints, as listed in the disclosure.

From an investor perspective, the key point is that this approval provides a framework for potential capital return via buybacks over multiple years; the real impact will depend on how much of the $75,000,000 limit is ultimately used and the timing of any repurchases within the period ending November 20, 2028.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MaxLinear (MXL) announce in this Form 8-K?

MaxLinear announced that its board of directors approved a share repurchase program authorizing the company to buy back up to $75 million of its common stock.

How large is MaxLinear's new share repurchase authorization?

The program allows MaxLinear to repurchase up to $75 million of its common stock, subject to conditions such as liquidity, share price, market conditions, and legal requirements.

Over what period can MaxLinear (MXL) repurchase shares under this program?

MaxLinear may repurchase shares under the program over a period ending on November 20, 2028.

How may MaxLinear execute the $75 million share repurchase program?

Repurchases may be made through open market purchases, block transactions, and privately negotiated transactions, including under Rule 10b5-1 trading plans in compliance with Rule 10b-18.

Is MaxLinear obligated to repurchase the full $75 million of stock?

No. The share repurchase program does not obligate MaxLinear to make any repurchases and may be modified, suspended, or terminated at any time without prior notice.

Where can investors find more details about MaxLinear's buyback program?

Additional details are provided in a press release that is filed as Exhibit 99.1 and incorporated by reference in the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/24/2025 - 08:31 AM EST Learn about SEC filing dates

0001288469false00012884692025-11-202025-11-200001288469exch:XNYS2025-11-202025-11-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

November 20, 2025

MaxLinear, Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-34666			14-1896129
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

5966 La Place Court, Suite 100, Carlsbad, California 92008

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (760) 692-0711

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $0.0001 par value			MXL			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On November 20, 2025, the board of directors of MaxLinear, Inc., (the “Company”) approved the repurchase of up to $75 million of the Company’s common stock over a period ending November 20, 2028. The program may be effected through open market purchases, block transactions, and privately negotiated transactions, in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), including through Rule 10b5-1 trading plans. The share repurchase program does not obligate the Company to make any repurchases and may be modified, suspended, or terminated by the Company at any time without prior notice. The amount and timing of repurchases are subject to a variety of factors including liquidity, share price, market conditions, and legal requirements.

The information contained in Item 8.01 of this Current Report on Form 8-K, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

A copy of the press release announcing the Company’s board of directors’ authorization of the share repurchase program is filed herewith as Exhibit 99.1 and is hereby incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits

Exhibit			Description
99.1			Press Release dated November 24, 2025
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:			November 24, 2025			MAXLINEAR, INC.
						(Registrant)
						By:			/s/ Steven Litchfield
									Steven Litchfield
									Chief Financial Officer and Chief Corporate Strategy Officer

3